Considerable variability in the efficacy of 8% capsaicin topical patches in the treatment of chronic pruritus in 3 patients with notalgia paresthetica
Andersen, Hjalte Holm; Sand, Carsten; Elberling, Jesper

Published in:
Annals of Dermatology

DOI (link to publication from Publisher):
10.5021/ad.2016.28.1.86

Creative Commons License
CC BY-NC 4.0

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):
Considerable Variability in the Efficacy of 8% Capsaicin Topical Patches in the Treatment of Chronic Pruritus in 3 Patients with Notalgia Paresthetica

Hjalte H. Andersen, Carsten Sand1, Jesper Elberling2

Center of Sensory-Motor Interaction, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, 1Dermato-venereological Department, Bispebjerg Hospital, Copenhagen, 2The Allergy Clinic, Copenhagen University Hospital Gentofte, Gentofte, Denmark

Notalgia paresthetica (NP) is a focal neuropathic itch condition manifesting in intense chronic or recurrent episodic itch in a hyperpigmented, macular, uni- or bilateral skin area located below and/or medially to the scapulae. Achieving satisfactory relieve in NP patients is challenging. In this case-series three female NP patients were treated with 8% capsaicin patches following a spatial quantification of their alloknetic area with a von Frey filament. The use of a von Frey filament in order to delimit the precise area of itch sensitization and thus patch application, proved clinically feasible. Although 8% topical capsaicin relieved itch in all three patients, the duration of the effectiveness varied greatly from only 3 days to >2 months. The treatment was well tolerated in the patients and there appear to be no significant hindrances to applying this treatment with NP as an indication, although it may only exhibit satisfactory effectiveness in certain patients. Placebo-controlled double-blinded trials are needed to confirm the effectiveness of the treatment and assess predictive parameters of the treatment outcome. (Ann Dermatol 28(1) 86~89, 2016)
as alloknesis, i.e. the perception of itch in response to normally innocuous stimuli, which is a concern for patient well-being and has not yet been assessed in patients with NP\(^1\). Here, the feasibility of using a 10 g Semmes-Weinstein nylon monofilament for sensory testing to map the area of alloknesis (similarly to the approach outlined in\(^3\)) as a psychophysical biomarker and specifically treating this area was assessed. The present case series describes three severe NP cases in which treatment with 8% capsaicin provided a clinically significant decrease in itch intensity and frequency, ranging in duration from 2 days to 3 months.

**CASE REPORT**

**Case 1**

A 54-year-old menopausal woman was referred due to long-standing intense itch, anatomically coinciding with hyperpigmentation of the upper right back (Fig. 1, 1A). The patient reported constant itch, rated 8 ∼ 10 on a visual analog scale (visual analogue scale [VAS], 0 ∼ 10; 0 denoting “no itch” and 10 denoting “worst imaginable itch”) and severe, consistent sleep difficulties due to frequent nocturnal bouts of itching.

Previous unsuccessful attempts to treat her NP-induced CP included topical treatment with antifungal, corticosteroid,
Fig. 2. Case 1 at follow-up (and 2nd treatment), 3 months following the initial treatment. Notice the significantly retracted area of alloknesis indicated by the black demarcation (Fig. 1A, B for comparison). The patient also exhibited diminished hyperpigmentation.

tacrolimus 0.1%, capsaicin 0.025%, and doxepin 5% creams. Only topical doxepin was shown to provide some relief (2 ~ 3 hours duration), but did not effectively relieve nightly bouts of itch. Histological examination of a 3-mm punch biopsy confirmed the presence of postinflammatory hyperpigmentation. The area of alloknesis was identified, which corresponded with the area of hyperpigmentation, except for a 2 ~ 4 cm border area with little or no hyperpigmentation.

After informed consent was obtained, the patient was treated with a topical 8% capsaicin patch for 1 hour. The treatment resulted in 7 weeks of complete itch relief, upon which a slow but steady reversal began. During re-examination and retreatment 3 months after the initial treatment, the patient reported that the returned CP was once again highly bothersome and sleep disruptive, but not entirely to the same extent as before the initial treatment. Of note, the intensity but not the area of the hyperpigmentation and the area of alloknesis to the nylon filament stimuli had diminished after the first treatment. Subsequent treatments with capsaicin 8% had comparable efficacy. By the third treatment, the area of alloknesis had retracted by approximately 15% ~ 25% (Fig. 2).

**Case 2**

A 49-year-old woman presented with itching and symmetrical bilateral hyperpigmentation below and medially to the scapulae (Fig. 1, 1B). She stated that the condition had emerged 5 ~ 6 years previously and reported 4 ~ 6 daily itch exacerbations, the itch intensity of which she rated at VAS = 9. The patient also expressed concerns regarding the implications of the discoloration on her aesthetic appearance. The patient had undergone topical and systemic antifungal therapies in previous unsuccessful attempts to treat her pruritus. A biopsy revealed postinflammatory hyperpigmentation. The area of alloknesis slightly exceeded the area of hyperpigmentation.

After obtaining informed consent, the patient was treated with a topical 8% capsaicin patch for 1 hour. At follow-up, the patient reported that her itch had disappeared completely for 1 week, and thereafter very slowly receded toward baseline levels. Despite this slow reversal, the patient reported that, at the 3-month follow-up/retreatment, her average itch intensity remained lower compared to her pretreatment baseline levels of itch. At retreatment after 3 months, both the hyperpigmentation and the area of alloknesis had decreased considerably.

**Case 3**

A 45-year-old woman was referred due to moderate itch of the upper back estimated to have persisted for approximately 20 years. The patient reported a constant itch rated at 3 on a VAS (0 ~ 10) and 1 ~ 3 daily itch exacerbations, the intensity of which she rated as 6 ~ 9. She reported experiencing typically two nightly itch-and-scratch bouts lasting several minutes each. She was taking no concomitant medication.

Inspection revealed no visible skin alterations in the area where the itch was perceived — medially to the left scapula (Fig. 1, 1C). The area of alloknesis could be identified using a 10 g nylon filament. After informed consent was obtained, the patient was treated with a topical 8% capsaicin patch for 1 hour. At follow-up, the patient reported that the itch had subsided completely for 2 days but thereafter rapidly returned to baseline levels. She underwent one additional treatment 3 months after with a similarly subpar treatment outcome.

**DISCUSSION**

Achieving satisfactory relief in patients suffering from neuropathic itch such as in NP is highly challenging. Etiologically, the involvement of the spinal nerves T2 ~ T6 in NP is quite evident, but the nature of the pathophysiology at play in NP is unclear. First, a reduced density of intra-epidermal sensory nerve fibers has been observed in NP-affected skin, which is paradoxically also a well-established reversible effect of high-concentration capsaicin. Second, older literature hypothesized musculoskeletal impingement of the thoracic nerves, but supporting evidence is
but similar response variation has been observed in the
treatment of post-herpetic neuralgia15. Of interest, as can
ced erythema did not evoke secondary hyperpigmentation
other side effects were reported, and the treatment-indu-
ced erythema did not evoke secondary hyperpigmentation
in any of the subjects. The underlying cause of this notice-
table difference in treatment response in NP is unknown,

ters. Qutenza (Astellas Pharma) was well tolerated by the patients, and
the duration of the alleviation varied considerably. Studies
exploring the potential prediction of treatment outcome to
high-concentration capsaicin are warranted, particularly in
light of the current price of the treatment. Qutenza
itsent beyond the hyperpigmented area, hinting that CP
in NP might present as an area of spontaneously occurring
itch with an area of alloknesis within its perimeter, where-
in touch-evoked but not spontaneous itching occurs, thus
making it less prone to frequent scratching and hence, to
inflammation-induced hyperpigmentation.

Because the sensation of itch has low spatial resolution,
identifying the location and exact area of itch is not a trivi-
al task, particularly in patients without hyperpigmentation.
It is concluded that it is clinically feasible to delimit the
area of alloknesis, i.e., the itch-hypersensitive area with a
10 g von Frey filament (Fodplejejedepotet HEWA, Gentofte,
Denmark) in patients with NP. Two noticeable ob-
servations were made in the NP-affected skin in response
to treatment. The area of hyperpigmentation diminished in
size and/or intensity, and accordingly, the area of allokne-
sis was significantly reduced. This indicates that these pa-
rameters, when present, could be of potential use as se-
verity/treatment response biomarkers if implemented in
the routine assessment of NP.

The three patients reported here all experienced immediate
relief of itch in response to 8% topical capsaicin, but the
duration of the alleviation varied considerably. Studies
exploring the potential prediction of treatment outcome to
high-concentration capsaicin are warranted, particularly in
light of the current price of the treatment. Qutenza
(Astellas Pharma) was well tolerated by the patients, and
there appear to be no significant hindrances to applying
this treatment with NP as an indication.

REFERENCES

1. Huesmann T, Cunha PR, Osada N, Huesmann M, Zanellato

tion paper of the International Forum for the Study of Itch.

3. Alai NN, Skinner HB, Nabil ST, Jeffes E, Shahrokni S, Saemi AM. Notalgia paresthetica associated with cervical
spinal stenosis and cervicothoracic disk disease at C4 through C7. Cutis 2010;85:77-81.

4. Loosmore MP, Bordeaux JS, Bernhard JD. Gabapentin
treatment for notalgia paresthetica, a common isolated
peripheral sensory neuropathy. J Eur Acad Dermatol Ven-

5. Savk E, Bolukbasi O, Akyol A, Karaman G. Open pilot
study on oxcarbazepine for the treatment of notalgia pares-

6. Savk E, Savk O, Sendur F. Transcutaneous electrical nerve
stimulation offers partial relief in notalgia paresthetica
patients with a relevant spinal pathology. J Dermatol 2007;
34:315-319.

7. Weinfield PK. Successful treatment of notalgia paresthetica
with botulinum toxin type A. Arch Dermatol 2007;143:
980-982.

8. Maari C, Marchessault P, Bissonnette R. Treatment of
notalgia paresthetica with botulinum toxin A: a double-
blind randomized controlled trial. J Am Acad Dermatol
2014;70:1139-1141.

9. Metz M, Krause K, Maurer M, Magel R. Treatment of
notalgia paresthetica with an 8% capsaicin patch. Br J

Dickenson AH. Unravelling the mystery of capsaicin: a tool
to understand and treat pain. Pharmacol Rev 2012;64:
939-971.

11. Uçeyler N, Sommer C. High-dose capsaicin for the treat-
ment of neuropathic pain: what we know and what we
need to know. Pain Ther 2014;3:73-84.

12. Andersen HH, Elberling J, Arendt-Nielsen L. Human Surro-
gate Models of Histaminergic and Non-histaminergic Itch.

13. Højland CR, Andersen HH, Poulsen JN, Arendt-Nielsen L,
Gazerani P. A Human Surrogate Model of Itch Utilizing the
TRPA1 Agonist Trans-cinnamaldehyde. Acta Derm Venereol


15. Raber JM, Reichelt D, Grüneberg-Oelker U, Philipp K,
Stubbe-Dräger B, Husstedt IW. Capsaicin 8% as a cuta-
neous patch (Qutenza™): analgesic effect on patients with
peripheral neuropathic pain. Acta Neurol Belg 2015;115:
335-343.